Annovis Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Annovis Bio, Inc. (ANVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $570.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2025-03-21
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $570.00K, a 48.73% decline from fiscal 2023.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.11M, a 38.38% increase from fiscal 2022.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $803.36K, a 92.80% decline from fiscal 2021.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $11.16M, a 5567.69% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2024-12-31 | $570.00K 10-K · filed 2025-03-21 |
| 2023-12-31 | $1.11M 10-K · filed 2024-03-29 |
| 2022-12-31 | $803.36K 10-K · filed 2024-03-29 |
| 2021-12-31 | $11.16M 10-K · filed 2023-03-31 |
| 2020-12-31 | $196.98K 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |